Brief: Mymd Pharmaceuticals® And Charles River Present Positive Data For Next Generation, Oral Tnf-Α Inhibitor Mymd-1® In Rheumatoid Arthritis
20/03/2023 12:56
March 20 (Reuters) - MyMD Pharmaceuticals Inc MYMD.O :
* MYMD PHARMACEUTICALS® AND CHARLES RIVER PRESENT POSITIVE
DATA
FOR NEXT GENERATION, ORAL TNF-Α INHIBITOR MYMD-1® IN RHEUMATOID
ARTHRITIS
* MYMD PHARMACEUTICALS - STUDY RESULTS SHOWED MYMD-1 REDUCED
HISTOPATHOLOGICAL CHANGES AND SEVERITY OF STANDARD ARTHRITIS
CLINICAL TRIAL MEASURES
Source text for Eikon: ID:nBw9CwQZPa
Further company coverage: MYMD.O
((Reuters.Briefs@thomsonreuters.com;;))